Planning Your Treatment
Another study suggests that lumpectomy plus radiation may offer survival benefits for some women diagnosed with early-stage disease.
A study has found that women diagnosed with inflammatory breast cancer who are treated with chemotherapy, surgery, and radiation have better survival rates than women who don't receive all three treatments.
ASCO has put out new guidelines on using biomarkers to make decisions about treatments after surgery for women diagnosed with early-stage invasive breast cancer.
A small, early study found that a tamoxifen gel applied directly to the breast area of women diagnosed with DCIS stopped cancer cell growth as well as tamoxifen pills and caused fewer side effects.
Many young women don't think hormonal therapy is an essential treatment for breast cancer, which may be why they stop the treatment early.
Women diagnosed with early-stage breast cancer in one breast who are treated with lumpectomy followed by radiation therapy have the same survival rates as women who are treated with double mastectomy.
U.S. legislators are considering two bills -- one on minimum hospital stays after breast cancer surgery and one on federal funding for environmental links to breast cancer -- that may have a big effect on women diagnosed with the disease.
A small study has found that most younger women diagnosed with early-stage breast cancer who decide to have the other healthy breast removed choose the surgery because they want to reduce their risk of breast cancer developing in the other breast and improve their survival, even though most of them know that removing the other healthy breast doesn't really improve survival rates in women without an abnormal breast cancer gene.
Taking Arimidex for 3 years after 5 years of tamoxifen reduced the risk of the cancer coming back in women diagnosed with hormone-receptor-positive breast cancer.
Removing the ovaries and taking tamoxifen after breast cancer surgery had benefits for premenopausal women shows a new study done in Vietnam and China.
Surgeons' characteristics seem to affect whether women receive radiation therapy after lumpectomy.
Many women overestimate the risk of DCIS coming back.
Whether or not a woman has sentinal lymph node biopsy seems to be largely influenced by her age, ethnicity, and insurance status, and not by the relevant disease factors, new research shows.
A small study suggests that prophylactic (protective) breast and ovary removal can be done safely during one surgery.
Women whose breasts look significantly different from each other after lumpectomy are more likely to be depressed and feel ashamed of their bodies.
Research suggests that many women diagnosed with early-stage breast cancer don't understand the differences in risks and benefits between mastectomy and lumpectomy and radiation therapy.
A new study shows that breast cancers that are hormone-receptor-positive and later-stage are more likely to come back later than 5 years after diagnosis and treatment compared to cancers that are hormone-receptor-negative and early-stage.
Women who had lumpectomy to treat an initial breast cancer and then had lumpectomy again to treat breast cancer that came back in the same breast had lower survival rates in the 10 years after the second surgery compared to women who had lumpectomy as the first surgery and then mastectomy as the second surgery.
A small study suggests that reconstruction done immediately after mastectomy using tissue from the body offers better results after radiation compared to immediate reconstruction using implants.
After 10 years of follow-up, research shows that 5 years of Arimidex is better at reducing the risk of hormone-receptor-positive breast cancer recurrence than 5 years of tamoxifen.
New research suggests that lymphedema may be more common and last longer than generally thought.
Research suggests that giving BOTH chemotherapy and radiation therapy before surgery to remove locally advanced breast cancer can help reduce the risk of the cancer coming back in the breast area in the 5 years after surgery.
Women diagnosed with early-stage, hormone-receptor-positive breast cancer who got 5 years of an aromatase inhibitor seem to be more likely to have heart problems compared to women who got 5 years of tamoxifen.
A new study shows that Arimidex and Aromasin are equally good at reducing the risk of recurrence in postmenopausal women diagnosed with early-stage, hormone-receptor-positive breast cancer.